Phibro Animal Health Corporation reported adjusted earnings per share of $0.85 for the fourth quarter ended June 30, 2026, up 26% year-over-year and exceeding Wall Street estimates of $0.72 by 18%. Revenue for the quarter totaled $396.7 million, a 5% increase from the prior year and ahead of the $382.51 million consensus by 3.7%.
Full-year fiscal 2026 net sales reached a record $1.518 billion, a 17% increase from the prior year, while adjusted EBITDA climbed 39% to $255 million. The animal health segment generated $1.162 billion in sales, up 21%, while mineral nutrition revenue rose 11% to $282.3 million. Performance products sales declined 8% to $73.5 million. Operating cash flow for the year was $69 million, with capital expenditures of $59 million resulting in free cash flow of $10 million.
The company’s Phibro Forward transformation program, concluded in June 2026, contributed approximately $50 million in cumulative EBITDA benefits. Inventory levels increased by $86.3 million, primarily due to the acquisition of Zoetis’ medicated feed additive portfolio, which contributed $354.3 million in full-year sales. The acquired portfolio’s fourth-quarter sales totaled $83.9 million, down 11% year-over-year.
For fiscal 2027, Phibro guided net sales to range between $1.55 billion and $1.6 billion, representing growth of 2% to 5%. Adjusted EBITDA is projected between $258 million and $268 million, a 1% to 5% increase, while adjusted diluted EPS is expected between $3.41 and $3.59. The company also announced plans to close its Chicago Heights plant, with expected annual savings of $15 million to $20 million once fully realized.
Phibro maintained its quarterly dividend at $0.12 per share, marking 13 consecutive years of payments. The company’s gross leverage ratio stood at 2.9 times, with net leverage at 2.6 times as of June 30, 2026. Shares traded at $36.72, up 1.75% on the day, roughly 29.9% above the 52-week low and 38.9% below the 52-week high.
